Project: Allosteric Inhibition of RAS Counteracts Neuroblastoma (NBL) Tumorigenesis
Mentor: John O'Bryan, Ph.D.
"Neuroblastomas (NBL) are one of the most common pediatric solid tumors. The tumor-promoting oncoprotein called RAS is implicated in the progression of this tumor. Our lab has identified a novel inhibitor for this protein that counteracts its function. Using this novel inhibitor, we are addressing the question of whether inhibition of RAS is a viable strategy for treating NBL tumors. We are using a variety of biochemical, molecular and cell biology approaches to answer this question. If our proposed studies are successful, our work may lead to new therapeutic strategies for treating this deadly pediatric cancer that is currently refractory to conventional therapies."
Project: Characterizing the Roles and Regulators of Protein Arginine Methyltransferase 5 (PRMT5) in Breast Cancer
Mentor: Wenjian Gan, Ph.D.
"Mostly breast tumors display higher PRMT5 (a coding gene) expression and the expression levels of PRMT5 are associated with poor prognosis and survival in triple-negative breast cancer. PRMT5 is believed to function largely as an oncogene. However, the exact mechanisms by which PRMT5 promotes breast tumorigenesis are unclear. This project will dissect the mechanisms and regulations of PRMT5 in breast cancers and expect to make some groundwork for the utility of PRMT5 inhibitor in the clinic."
Project: LncRNA Regulatlon of Glycolysis in Breast Cancer
Mentor: Je-Hyun Yoon, Ph.D.
"This research investigates the therapeutic strategy for malignant breast cancer by revealing the pivotal roles of long noncoding RNA (lncRNA) NEAT1 in glucose metabolism and cancer development. Aberrant metabolic program strongly associated with breast cancer correlates with enhanced tumorigenesis, relapse and resistance to treatment by targeting lncRNAs. This project will provide new therapeutic approach and help overcome resistance to treatment of malignant breast cancer."
Project: Investigating the role of stromal IL-6 in the immune evasion and progression of pancreatic cancer
Mentor: Michael Ostrowski, Ph.D.
"Pancreatic adenocarcinoma (PDAC) is one of the most lethal and recalcitrant cancer types. This is in part due to the development of a dense stroma and significant degree of immunosuppression. My research will determine how expression of the pleotropic cytokine IL-6 by fibroblasts, specifically within the stroma, contributes to the progression and immune cell population of PDAC tumors."
Project: Dissecting an Fbxo4-hnRNPK regulatory axis in oral squamous carcinoma
Mentor: J. Alan Diehl, Ph.D.
"Mucha’s research investigates hnRNP K, a multifunctional RNA binding protein that increases it’s response in many human cancers. Preliminary data revealed that hnRNP K is modified by Fbxo4-dependent ubiquitylation. The focus of his current research project is to reveal the nature of the polyubiquitin chains and the reaction of Fbxo4-dependent regulation of hnRNP K for normal versus tumor cell growth."
Project: NF-kB function in muscle stem cells regulates macrophages to promote cancer Cachexia
Mentor: Denis Guttridge, Ph.D.
"The goal of Pryce’s research is to explore muscle wasting in cancer, a condition called cachexia. Cachexia greatly decreases survival and quality of life in cancer patients, which is especially prominent in pancreatic cancer. His project will focus on the role of the NF-kB signaling pathway and how it contributes to cachexia in pancreatic cancer as well as other cancers."
Project: Transfer RNAs in Cell Plasticity and Tumor Progression: Uncharted Biology and Novel Therapeutic Avenues
Mentor: Philip Howe, Ph.D.
"The aim of Dr. Grelet's project is to decipher how tRNA biology regulates cancer invasion and stemness, two traits of the tumor cells that are deemed to be essential during tumor metastasis and tumor relapse. Such molecular insights might open new therapeutic opportunities that will be evaluated within the study."
Project: Structural Biology of the Essential Cell Cycle Regulator Cdc34
Mentor: Shaun Olsen, Ph.D.
"I study structure and function of protein complexes in ubiquitin pathway and develop inhibitor for cancer therapeutic targets."
Project: Targeting STING in Immunotherapy for Hematologic Malignancy
Mentor: Xue-Zhong Yu, M.D.
"The goal of this proposal is to define the biology of stimulator of interferon gene (STING) in immune response against leukemia after bone marrow transplantation (BMT). We will validate STING as a potential target in immunotherapy for controlling leukemia relapse and reducing the side effects associated with BMT."